olodaterol
Trade name: striverdi respimat
Approved
Jul 31, 2014
Olodaterol is a beta2-adrenoceptor agonist discovered by Boehringer Ingelheim and approved for the treatment of Chronic Obstructive Pulmonary Disease. The compound exerts its pharmacological effects by binding and activation of beta2-adrenoceptors after inhalation. Activation of these receptors in the airways results in a stimulation of intracellular adenyl cyclase, an enzyme that mediates the synthesis of cyclic-3’, 5’ adenosine monophosphate (cAMP). Elevated levels of cAMP induce bronchodilation by relaxation of airway smooth muscle cells. Olodaterol effect lasts for 24 hours. — NCATS
Clinical trial activity
75 trials · 15 clinical orgs · 1 marketing orgs
Earliest trial started Feb 1, 2005 (NCT02171780)
Timeline
2000s
- Jan 1, 2005
Boehringer Ingelheim — Earliest Phase 1 Sponsor(trial)
- Jan 1, 2005
Boehringer Ingelheim — Earliest Phase 2 Sponsor(trial)
- Jan 1, 2008
Boehringer Ingelheim — Earliest Phase 3 Sponsor(trial)
2010s
- Jul 31, 2014
Boehringer Ingelheim — Earliest FDA Approval
- Jul 31, 2014
Boehringer Ingelheim — NDA Secondary Org
- Jul 31, 2014
Boehringer Ingelheim — NDA Organization
Indications
Mechanism of action
- Beta-2 adrenergic receptorAGONIST
ADRB2 agonist
Long-acting
Combination products
stiolto respimat
with tiotropium
Also known as spiolto respimat
Approval history
- approvedJul 31, 2014
Chemistry & pharmacology
SMILES
COc1ccc(CC(C)(C)NC[C@H](O)c2cc(O)cc3c2OCC(=O)N3)cc1- Mol. weight
- 386.45 g/mol
- Lipinski Ro5
- Pass
- Rule of 3
- No
- Chirality
- Single Stereoisomer
- Inorganic
- No
- Polymer
- No
- Delivery
- Topical
- Availability
- Prescription Only
Oral
No
Parenteral
No
Topical
Yes
Sources
- ChEMBLCHEMBL605846 ↗
- WikipediaOlodaterol ↗
- NCATSVD2YSN1AFD ↗
- ChEMBLCHEMBL2105743 ↗
Also known as
- 6-hydroxy-8-(1-hydroxy-2-((2-(4-methoxyphenyl)-1,1-dimethylethyl)amino)ethyl)-2h-1,4-benzoxazin-3(4h)-one
- bi1744
- bi 1744
- bi 1744
- bi 1744
- bi-1744
- bi-1744
- bi-1744
- bi 1744 cl
- bi 1744 cl
- bi 1744 cl
- bi 1744 cl
- bi-1744 cl
- bi-1744-cl
- bi-1744-cl
- olodaterol
- olodaterol
- olodaterol
- olodaterol
- olodaterol
- olodaterol
- olodaterol
- olodaterol
- olodaterol
- olodaterol
- olodaterol hcl
- olodaterol hcl
- olodaterol hcl
- olodaterol hydrochloride
- olodaterol hydrochloride
- olodaterol hydrochloride
- olodaterol hydrochloride
- striverdi respimat
- striverdi respimat
- striverdi respimat
- striverdi respimat
- striverdi respimat
Clinical trials
| NCT ID | Phase | Start date | Sponsor(s) |
|---|---|---|---|
| NCT07267130 | Phase 1 | Nov 25, 2025 | Jiangsu Chia-tai Tianqing Pharmaceutical Co.,Ltd |
| NCT04994574 | N/A | Aug 31, 2021 | Yonsei University |
| NCT05295355 | N/A | Jan 25, 2021 | Boehringer Ingelheim, Guangzhou Medical University |
| NCT04231214 | Phase 4 | Feb 1, 2020 | Boehringer Ingelheim, Fraunhofer |
| NCT04223843 | Phase 4 | Jan 10, 2020 | Boehringer Ingelheim |
| NCT03842839 | N/A | Oct 1, 2018 | Guangzhou Medical University |
| NCT03662711 | Phase 4 | Sep 30, 2018 | University of Ferrara |
| NCT03673670 | Phase 2 | Jul 16, 2018 | University of Manchester, Verona Pharma plc |
| NCT03265145 | Phase 4 | Sep 20, 2017 | Boehringer Ingelheim, HealthCore-Anthem Research Network |
| NCT03240575 | Phase 4 | Aug 14, 2017 | Boehringer Ingelheim |
| NCT03152149 | Phase 4 | Jun 1, 2017 | Boehringer Ingelheim, University of Dundee |
| NCT03055988 | Phase 4 | Mar 29, 2017 | Boehringer Ingelheim |
| NCT02969317 | Phase 1 | Feb 24, 2017 | Boehringer Ingelheim |
| NCT03425617 | Phase 4 | Jan 1, 2017 | Boehringer Ingelheim, Queen's University, Belfast |
| NCT02853123 | Phase 4 | Sep 22, 2016 | Boehringer Ingelheim |
| NCT02812862 | Phase 4 | Aug 31, 2016 | RWTH Aachen University |
| NCT02845752 | Phase 4 | Aug 1, 2016 | Boehringer Ingelheim, Los Angeles Biomedical Research Institute, University of California, Los Angeles |
| NCT02682862 | Phase 4 | Aug 1, 2016 | University of Dundee |
| NCT02799784 | Phase 4 | Jul 14, 2016 | GlaxoSmithKline |
| NCT02683109 | Phase 4 | Mar 8, 2016 | Boehringer Ingelheim |
Organizations
Research & Development (15)
| Organization | Org type | Trials | As lead sponsor | Phases | Earliest year |
|---|---|---|---|---|---|
| Boehringer Ingelheim | For profit | 67 | 62 | 5 | 2005 |
| Guangzhou Medical University | Academic/Hospital | 2 | 2 | 1 | 2018 |
| University of Dundee | Academic/Hospital | 2 | 2 | 1 | 2016 |
| Fraunhofer | For profit | 1 | 1 | 1 | 2020 |
| GlaxoSmithKline | For profit | 1 | 1 | 1 | 2016 |
| HealthCore-Anthem Research Network | Academic/Hospital | 1 | 0 | 1 | 2017 |
| Jiangsu Chia-tai Tianqing Pharmaceutical Co.,Ltd | For profit | 1 | 1 | 1 | 2025 |
| Los Angeles Biomedical Research Institute | Academic/Hospital | 1 | 1 | 1 | 2016 |
| Queen's University, Belfast | Academic/Hospital | 1 | 1 | 1 | 2017 |
| RWTH Aachen University | Academic/Hospital | 1 | 1 | 1 | 2016 |
| University of California, Los Angeles | Academic/Hospital | 1 | 0 | 1 | 2016 |
| University of Ferrara | Academic/Hospital | 1 | 1 | 1 | 2018 |
| University of Manchester | Academic/Hospital | 1 | 0 | 1 | 2018 |
| Verona Pharma plc | For profit | 1 | 1 | 1 | 2018 |
| Yonsei University | Academic/Hospital | 1 | 1 | 1 | 2021 |
Marketing (2)
| Organization | Org type | Relationship | Date |
|---|---|---|---|
| Boehringer Ingelheim | For profit | NDA2 | Jul 31, 2014 |
| Boehringer Ingelheim | For profit | NDA | Jul 31, 2014 |